T Cell News and Research

Latest T Cell News and Research

The potential of mRNA vaccines for a wide range of diseases

A new review article published in the journal Briefings in Functional Genomics focuses on the general characteristic features and mechanisms of mRNA vaccines. Further, this review has summarized the current progress of mRNA vaccines that have been developed for wide-ranging diseases, including COVID-19 disease.

8 Jun 2021

Antihistamines might be effective in long-COVID

A team of scientists from the United Kingdom has recently revealed the therapeutic benefits of histamine receptor antagonists in reducing long-term symptoms of coronavirus disease 2019 (COVID-19). They have also indicated that T cell immune responses to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection vary between asymptomatic COVID-19 and long-COVID.

8 Jun 2021

How SARS-CoV-2 variant B.1.1.7 adapted to evade innate immunity

Researchers in the United States and the UK have conducted a study showing how the B.1.1.7 (Alpha) lineage of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) adapted to suppress host innate immune responses in lung epithelial cells.

8 Jun 2021

Researchers identify a novel host-directed therapeutic approach to COVID-19

Researchers in the UK have demonstrated the potential of modulating the expression of angiotensin-converting enzyme 2 (ACE2) as a novel host-directed therapeutic approach to protecting against coronavirus disease 2019 (COVID-19).

8 Jun 2021

Cell-to-cell contact helps in spreading SARS-CoV-2, finds study

People aren’t the only ones who should be social distancing — new research shows our cells need to as well. Researchers from Ohio State University in Columbus, Ohio, USA, used in-culture techniques to confirm SARS-CoV-2 transmission via cell-to-cell contact.

8 Jun 2021

What lessons have we learned over a year into the COVID-19 pandemic?

One of the pressing questions scientists are currently trying to answer is whether the current vaccines will remain effective against the emerging SARS-CoV-2 variants of concern. A new piece of research has been published in the journal Biomedicines, which discusses the knowledge we have gained thus far and the questions that researchers should address in future work.

8 Jun 2021

Treating critically ill COVID-19 patients with non-altered umbilical cord stem cells increases survival

Critically ill COVID-19 patients treated with non-altered stem cells from umbilical cord connective tissue were more than twice as likely to survive as those who did not have the treatment, according to a study published today in STEM CELLS Translational Medicine.

8 Jun 2021

What is the role of monoclonal antibody therapy in treating COVID-19?

A new study has been published in the journal Vaccines that deals with the present state of research on using mAbs for the treatment of the COVID-19 disease. Many clinical trials are being conducted to evaluate the efficacy and safety of several newly designed mAbs. Some of the mAbs are directed towards immune system responses, i.e., non-SARS-CoV-2 specific mAbs, while others are devised to neutralize the SARS-CoV-2 protein structure, i.e., SARS-CoV-2 specific mAbs.

8 Jun 2021

Could the intranasal route be an alternate avenue of COVID-19 vaccination?

A new study has been published in the journal Vaccines that summarizes the history of vaccines, reviews the current progress in COVID-19 vaccine technology, and discusses the status of intranasal COVID-19 vaccines as a potential pathway to immunization.

8 Jun 2021

Researchers review environmental risk assessments for recombinant COVID-19 viral vector vaccines

In a recent review, published in the journal Vaccines, researchers in Belgium look at the recombinant viral vector-vaccine candidates that are primarily against SARS-CoV-2 still in development and discuss their features from an environmental risk point of view.

8 Jun 2021

Iksuda Therapeutics closes $47 million financing round

Iksuda Therapeutics (Iksuda) has announced it has completed a US $47 million (circa GB £34 million) financing round, co-led by Mirae Asset Capital and its subsidiaries, Celltrion and Premier Partners, with the Company being advised by Ashfords LLP. The funding will support the advancement of Iksuda’s lead ADC assets and expansion of its payload and conjugation platform technologies.

From Iksuda Therapeutics 8 Jun 2021

Immunomodulatory therapies for nephrological autoimmune diseases may help treat severe COVID-19

Various viruses and bacteria have long been known to cause autoimmune diseases where there is such a predisposition. This phenomenon also seems to play a major role in SARS-CoV-2, especially in severe courses.

8 Jun 2021

New study could help guide oncologists in selecting the best treatment for kidney cancers

Not all kidney cancers behave the same, with wildly different responses to immunotherapy or other treatments – and wildly different outcomes for patients as a result.

8 Jun 2021

Drug sensitivity of hepatocellular cancer cells may provide new insights on tumor biology

Oncotarget published "Effect of cell microenvironment on the drug sensitivity of hepatocellular cancer cells" which reported that this study aimed to investigate whether Hepatocellular Cancer (HCC) cells cultured in more native conditions have an altered phenotype and drug sensitivity compared to those cultured in standard conditions.

8 Jun 2021

Lymphangiogenesis predicts favorable outcomes to immunotherapy

Oncotarget published "Mutually exclusive lymphangiogenesis or perineural infiltration in human skin squamous-cell carcinoma" which reported that although tumor-associated lymphangiogenesis correlates with metastasis and poor prognosis in several cancers, it also supports T cell infiltration into the tumor and predicts favorable outcome to immunotherapy.

8 Jun 2021

NIH researchers identify novel small molecule inhibitors of SARS-CoV-2 variants

A team of scientists from the National Institutes of Health (NIH), USA, has recently identified six novel small molecule inhibitors of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and its variants. The study is currently available on the bioRxiv* preprint server.

8 Jun 2021

New chip mimicking bovine endometrium could play key role in cattle’s pregnancy success

To investigate factors that can jeopardize pregnancy success in cattle, researchers at the University of São Paulo (USP) in Brazil used a kind of chip to mimic the environment of the endometrium, the tissue that lines the inside of the uterus.

8 Jun 2021

New method successfully reversed male infertility in mice

The ability of stem cells to fix impaired functions of host tissues after transplantation has been a lifesaving breakthrough in treating previously incurable conditions. Much like a coin toss, however, the fate of the transplanted stem cells is unpredictable. They may choose self-renewal, grow into a different kind of tissue, or die.

8 Jun 2021

Study confirms the importance of low-protein, high-carbohydrate diet

Researchers at the University of Sydney's Charles Perkins Centre conducted the largest ever study of nutrient interactions by examining the health of mice on 33 different diets containing various combinations of protein to carbs, and different sources of carbohydrate.

8 Jun 2021

ACE2 functions as a gateway for COVID-19 virus

Normally, the ACE2 enzyme helps regulate our blood pressure. The enzyme sits on the surface of cells, including cells in the lungs, but in connection with COVID-19 it has been found that ACE2 also functions as a gateway for the virus.

8 Jun 2021